Track Boston Scientific's common stock ($17M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
The latest common stock for BSX is $17M as of June 2026. That compares with $17M in the prior-year period — up 0.0% year over year. Investors often review this figure alongside Boston Scientific's historical trend and sector peers before judging valuation or financial health.
Over the past year, BSX's common stock moved from $17M to $17M — essentially flat versus a year earlier. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Boston Scientific's operating scale or balance-sheet position.
A common stock figure of $17M for BSX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting BSX's common stock ($17M), review year-over-year change from $17M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Boston Scientific's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.